Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 6 June 2016, 22:17 HKT/SGT
Share:
"One Belt One Road" Fund & Cooperation Signing Ceremony Held; China Baoli Designated Investment Manager

HONG KONG, June 6, 2016 - (ACN Newswire) - The "One Belt One Road" Investment Fund (the "Fund") & Strategic Cooperation Signing Ceremony, was held today at the Hong Kong Four Seasons Hotel. China CYTS Industrial Development Co., Ltd. ("China CYTS"), the Fund Sponsor, signed strategic cooperation agreements with RT-Business Development LLC ("Rostec"), Russia's state-owned industrial and technologies company, bringing bilateral technological and investing cooperation to a new level; and China Baoli Technologies Holdings Ltd. ("China Baoli"), as designated investment manager of the Fund.

(left to right): Mr. YEUNG Chun Wai, Anthony (Executive Director of China Baoli Technologies Holdings Limited); Mr. ZHAO Zong Hui (President of China CYTS Industrial Development Co., Ltd.); Mr. Andrey Korobov (CEO of RT-Business Development LLC)


China CYTS acted jointly with another large state-owned enterprise as Sponsor to launch the Fund, which will focus on industrial and new-industry investment projects in countries and regions connected to the 'Silk Road Economic Belt' and '21st Century Maritime Silk Road', and aims at capitalizing on investment opportunities related to the "One Belt One Road" national strategy.

As the Fund's designated investment manager, China Baoli will assist China CYTS in the completion of fund raising and the Fund's day-to-day management and investment operations. The Fund targets at an initial size of US$4 billion, of which China CYTS will contribute US$500 million as a subordinated limited partner.

China CYTS (China Youth Travel) is a company directly owned by the Communist Youth League Central State Holding Co., incorporated in the People's Republic of China, with strong background, network, resources and financial support. It has investments in a wide range of sectors, including logistics, education, healthcare, gold trading and internet banking.

China Baoli is an investment holding company listed on the main board of the Hong Kong Stock Exchange [HK:164]. It is principally engaged in the entertainment business, including cruise ship management and gamma ray irradiation services, as well as the development of the Yota smartphone and related businesses. The Company is actively looking for new investments and business opportunities to enhance shareholders' value in the long run.



Topic: Press release summary Sectors: Daily Finance, Funds & Equities, Banking & Insurance
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets  
Feb 6, 2026 17:45 HKT/SGT
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share  
Feb 6, 2026 17:01 HKT/SGT
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization  
Feb 6, 2026 16:34 HKT/SGT
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis  
Feb 6, 2026 14:17 HKT/SGT
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025  
Feb 6, 2026 13:13 HKT/SGT
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market  
Friday, February 6, 2026 12:34:00 PM
Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market  
Feb 6, 2026 12:21 HKT/SGT
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors  
Feb 6, 2026 11:44 HKT/SGT
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products  
Friday, February 6, 2026 10:50:00 AM
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan  
Friday, February 6, 2026 10:31:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: